LakeShore Biopharma Sets February 12 EGM to Approve Going-Private Merger

An announcement from LakeShore Biopharma ( (LSBCF) ) is now available.

On January 20, 2026, LakeShore Biopharma announced it has called an extraordinary general meeting of shareholders for February 12, 2026 in Beijing to vote on authorizing and approving its previously announced merger agreement with Oceanpine Skyline Inc. and its subsidiary, Oceanpine Merger Sub Inc. Under the proposed deal, Oceanpine Merger Sub would merge into LakeShore Biopharma, which would survive as a wholly owned subsidiary of Oceanpine Skyline and transition to a privately held company, with its ordinary shares and warrants delisted from OTC markets and deregistered under the U.S. Securities Exchange Act. The board of directors, acting on the unanimous recommendation of a special committee of independent directors, has approved the merger documents and is urging shareholders of record as of January 16, 2026 to vote in favor of the transaction, a step that could significantly reshape the company’s capital-market profile and governance structure by taking it out of the public equity markets.

The most recent analyst rating on (LSBCF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSBCF Stock Forecast page.

Spark’s Take on LSBCF Stock

According to Spark, TipRanks’ AI Analyst, LSBCF is a Neutral.

LakeShore Biopharma’s overall stock score is primarily impacted by its financial performance, which shows strong gross profit margins but significant challenges with profitability and cash flow. Technical analysis indicates a bearish trend, and the lack of valuation data further contributes to a lower score. The absence of earnings call and corporate events data means these components do not influence the score.

To see Spark’s full report on LSBCF stock, click here.

More about LakeShore Biopharma

LakeShore Biopharma Co., Ltd., formerly YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. Leveraging its proprietary PIKA® immunomodulating technology platform, the company is advancing preventive and therapeutic biologics targeting rabies, hepatitis B, influenza and other viral infections, and operates across China, Singapore and the Philippines under a management team with both local and international industry experience.

Average Trading Volume: 4,216

Technical Sentiment Signal: Sell

Current Market Cap: $34.93M

For an in-depth examination of LSBCF stock, go to TipRanks’ Overview page.